基石藥業-B(02616.HK):近期獲首席執行官兼執行董事楊建新增持57.25萬股
格隆匯10月25日丨基石藥業-B(02616.HK)公吿,公司獲首席執行官兼執行董事楊建新吿知,其分別於2022年10月19日、10月20日、10月21日及10月24日以其自有資金在公開市場上購買合共57.25萬股股份。楊建新進行上述股份購買後,其自2022年9月已在公開市場上購買合共157.25萬股股份且其於公司的持股權益佔公司於公吿日期的已發行股本總額約3.85%。
楊建新向公司表示,其對公司的未來前景充滿信心,而增持公司股份代表其相信在複雜多變的市場環境中公司有能力持續保持穩健經營的同時實現快速的增長以及對公司的增長及發展的不懈支持。楊建新並不排除其可能適時進一步增持公司股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.